2012
DOI: 10.1155/2012/479712
|View full text |Cite
|
Sign up to set email alerts
|

Abstract: β-nitrostyrene compounds, such as 3,4-methylenedioxy-β-nitrostyrene (MNS), inhibit growth and induce apoptosis in tumor cells, but no reports have investigated their role in osteosarcoma. In this study, human osteosarcoma cell families with cell lines of varying tumorigenic and metastatic potential were utilized. Scrape motility assays, colony formation assays, and colony survival assays were performed with osteosarcoma cell lines, both in the presence and absence of MNS. Effects of MNS on human osteoblasts an… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
2

Citation Types

0
8
0

Year Published

2015
2015
2022
2022

Publication Types

Select...
6

Relationship

0
6

Authors

Journals

citations
Cited by 9 publications
(8 citation statements)
references
References 43 publications
0
8
0
Order By: Relevance
“…A number of similar 1,3-benzodioxole derivatives have demonstrated anti-tumor activity by various mechanisms, including binding to tubulin and heat-shock protein inhibition [23-25]. In addition, the trans-β-Nitrostyrene domain possessed by SXT1596 has been observed in related compounds to inhibit protein phosphatases [26] and telomerase [27], resulting in anti-tumor action in several cancer subtypes [28-30]. Whether the compound directly inhibits the SS18-SSX/TLE1 interaction domain or disrupts the complex by a secondary mechanism is currently unknown, but the structure of SXT1596 indicates that it is likely a covalent protein inhibitor, not expected to be well tolerated until further pharmacologic optimization steps are carried out [31].…”
Section: Discussionmentioning
confidence: 99%
“…A number of similar 1,3-benzodioxole derivatives have demonstrated anti-tumor activity by various mechanisms, including binding to tubulin and heat-shock protein inhibition [23-25]. In addition, the trans-β-Nitrostyrene domain possessed by SXT1596 has been observed in related compounds to inhibit protein phosphatases [26] and telomerase [27], resulting in anti-tumor action in several cancer subtypes [28-30]. Whether the compound directly inhibits the SS18-SSX/TLE1 interaction domain or disrupts the complex by a secondary mechanism is currently unknown, but the structure of SXT1596 indicates that it is likely a covalent protein inhibitor, not expected to be well tolerated until further pharmacologic optimization steps are carried out [31].…”
Section: Discussionmentioning
confidence: 99%
“…1A), as it was recently suggested to suppress the growth of human triple negative breast cancer cells (MDA-MD-231) by inhibiting PDI [19]. MNS is one of many nitrostyrene derivatives that have been considered for therapeutic use [3437], and has also been reported to suppress platelet aggregation and activation of the NLRP3 inflammasome activation [38,39], to inhibit protein tyrosine kinase [39] and monoamine oxidase B [40], to attenuate tumor growth [41], and to slow mobility and colony formation in osteosarcoma cells [42]. …”
Section: Introductionmentioning
confidence: 99%
“…Chou and Deshaies reported that MNS inhibits AAA-type ATPase p97 and thus suppresses endoplasmic reticulum (ER)-associated degradation pathway, which may induce ER stress in cancer cells [22]. In human osteosarcoma cells, MNS decreases cell motility and colony formation [23]. We show here that MNS profoundly inhibited cell adhesion, migration, and invasion in human breast cancer cells.…”
Section: Introductionmentioning
confidence: 48%